Aim: to evaluate the effect of hypoxia-inducible factor-1α (HIF-1α) suppression by inhibiting cyclooxygenase-2 (COX-2) on lung inflammation in COPD model. Methods: Model of COPD was induced in rats by nitrogen dioxide (15-19 ppm) exposure: three 30-min exposures/day with 30-min intervals for 90 days. Celecoxib (C) was used as a COX-2 inhibitor. From 30th to 90th day rats of 1st group received C via esophageal probe, rats of 2nd group (control) received 0,9% NaCl. 3rd group was intact. Bronchoalveolar lavage fluid (BALF) cytogram was determined. The levels of COX-2, HIF-1α, IL-17, surfactant protein D (SP-D) were measured in BALF by ELISA. Results: Treatment with C decreased COX-2 level in BALF: 8,2±1,9 vs. 27,3±2,1 pg/ml in control group, p<0,05 (intact group 15,9±1,3 pg/ml). As a result of C therapy neutrophil content in BALF decreased to 10,3±1,1 % vs. 40,3±4,7 % in control group, p<0,05 (intact group 5,2±0,5 %); HIF-1α - 0,37±0,04 vs. 1,98±0,21 pg/ml, p<0,05, respectively (intact group 0,59±0,14 pg/ml); IL-17 - 49,9±8,2 vs. 110,7±17,1 pg/ml, p<0,05 (intact group 71,6±6,7 pg/ml) respectively. In contrast, the level of SP-D increased up to 143,6±8,7 vs. 61,8±4,9 pg/ml in control group, p<0,05 (intact group 83,7±7,9 pg/ml). The increase of SP-D concentration can be a consequence of the bronchoalveolar epithelium structure restoration. Conclusion: The inhibition of COX-2 had a suppressive effect on HIF-1α-signaling and lung inflammation. The results confirm the functional-regulatory relationship of HIF-1α- and COX-2-signaling cascades that can be a therapeutic target for preventing the progression of inflammation and airway remodeling in COPD.